Page 6 - Glenmark Pharmaceuticals

Glenmark, Pfizer launch Abrocitinib in India for Atopic Dermatitis

The prevalence of atopic dermatitis in India has risen over the past three decades, with approximately 5.9 per cent of adults affected, of which 4.4 per cent suffer from a severe form of the disease

Battle shifts to new class of drugs in diabetes treatment in India

Glenmark Pharmaceuticals launched a biosimilar version of liraglutide earlier this month, after getting the nod from the Drugs Controller General of India (DCGI)

Glenmark expands global reach with cancer drug Envafolimab agreement

Envafolimab is a first-in-class PD-L1 inhibitor, a type of immunotherapy drug that harnesses the body's immune system to fight cancer

Glenmark cuts diabetes drug cost by 70% with first Indian biosimilar launch

Drug, marketed under the brand name Lirafit, is priced at approximately Rs 100 for a standard daily dose of 1.2 mg

Glenmark Pharmaceuticals launches antidiabetic drug 'Lirafit' in India

Glenmark Pharmaceuticals on Wednesday said it has launched a biosimilar of the popular antidiabetic drug, Liraglutide in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement. It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed. Lirafit will be available only under prescription. "Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said. Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added. "W

Dr Reddy's, Glenmark recall products in US due to manufacturing issues

Dr Reddy's Laboratories, Glenmark Pharma and Zydus are recalling products in the US market for manufacturing issues, according to the US Food and Drug Administration (USFDA). In its latest enforcement report, the US health regulator said Princeton-based Dr Reddy's Laboratories, Inc, a unit of the Hyderabad-based drug firm, is recalling 1,656 bottles of Montelukast sodium tablets. The product is indicated to prevent wheezing, breathing difficulty, chest tightness, and coughing caused by asthma in adults. As per the USFDA, the company is recalling the affected lot due to "the presence of foreign tablets and capsules." A foreign tablet was found in a bottle of Montelukast sodium tablets, USP 10mg, identified as metoprolol 25 mg, it added. The company initiated the Class II voluntary recall on October 13 this year. The USFDA noted that Mahwah-based Glenmark Pharmaceuticals Inc, USA, a unit of Mumbai-based Glenmark Pharma, is recalling 5,856 bottles of Deferasirox tablets for oral ...

India's Glenmark Pharma posts Q2 loss on exceptional legal costs

Glenmark incurred an exceptional cost of Rs 325 crore, during the quarter, related to a legal case settlement with US DoJ, Antitrust Division and remediation costs at manufacturing sites

Glenmark Pharmaceuticals receives USFDA approval for generic Prolixin

Prolixin is a prescription medication used to treat schizophrenia and other mental/mood disorders

Glenmark Pharma launches triple-combination drug for Type 2 Diabetes

Medication will be sold under the brand name Zita DM, will be priced at Rs 14 per tablet

Stocks to Watch today: Bajaj Finance, LTTS, Zensar, HUDCO, Glenmark, Biocon

Stocks to watch on Wednesday, October 18, 2023: Bajaj Auto, Bandhan Bank, IndusInd Bank, LTIMindtree and Wipro to be in focus ahead of Q2 results today.

Glenmark gets USFDA nod to market generic version of Otezla tablets

Glenmark's current portfolio includes a total of 188 products that have been authorised for distribution in the US marketplace

Ichnos Sciences, Astria Therapeutics sign licensing deal for OX40 portfolio

Ichnos is set to receive $320 million upfront for development, regulatory and sales payments, coupled with low double-digit royalties

Glenmark Pharma soars 10% after S&P Global upgrades outlook to positive

The rating agency expects Glenmark to significantly reduce debt on completion of the GLS sale and maintain healthy earnings.

Glenmark, Cosmo partner to bring acne treatment Winlevi to Europe, S Africa

This agreement grants Glenmark the exclusive right to commercialise Winlevi in 15 EU countries, South Africa, and the UK

Glenmark announces license agreements for Winlevi in Europe and S Africa

Cassiopea, a subsidiary of Cosmo, will receive an upfront payment of $5 million and agreed double-digit royalties on net sales

Glenmark Pharma's life sciences arm deal may hit FY25 revenue estimates

But it will have additional cash to recalibrate its innovative pipeline

Glenmark Pharma slips 5% on inking deal to sell 75% stake GLS to Nirma

The company announced that it will sell 75 per cent stake in Glenmark Life Sciences (GLS) to Nirma for Rs 5,652 crore at Rs 615 per share.

Glenmark Pharma to sell 75% stake in GLS to Nirma for Rs 5,651 crore

Deal size estimated to be Rs 5,651 crore, valuing API arm at Rs 7,535 crore

Glenmark eyes double-digit revenue growth; to focus on debt reduction

Glenmark Pharmaceuticals aims to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year, according to Chairman and Managing Director Glenn Saldanha. The Mumbai-based drug major is also looking at enhancing EBITDA margins while expanding presence in various therapeutic segments like oncology and dermatology. "For the new financial year, we aim to grow by 10-11 per cent in revenues, expand our EBITDA margin to 19-20 per cent, and continue to focus on enhancing free cash generation for further debt reduction," Saldanha said in the company's Annual Report for FY23. In FY23, the company's consolidated revenue from operations stood at Rs 12,990 crore, up from Rs 12,305 crore in FY22. Besides, the drug maker reported an EBITDA of Rs 2,278 crore during the 2022-23 fiscal with margins at 17.5 per cent. Glenmark reported net debt of Rs 2,905 crore for the fiscal ended March 31, 2023. Addressing the company's shareholders, he not

Glenmark recalls 1,200 bottles of generic hypertension drug in US

Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA). The New Jersey-based arm of the drug firm is recalling 1,200 bottles of Trandolapril and Verapamil Hydrochloride extended-release tablets, as per the latest Enforcement Report of the US health regulator. The affected lot has been manufactured at the Goa plant of the Mumbai-based drug firm and then supplied to Glenmark Pharmaceuticals Inc, USA, the USFDA said. The firm is recalling the affected bottles due to it being "Subpotent", it noted. Glenmark Pharmaceuticals Inc initiated the nationwide (US) Class III recall on August 14 this year, it added. As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".